Accretion Nutraveda, a company in the Pharmaceuticals industry, reported revenue of ₹29 crore and net profit of ₹4.73 crore for the September 2026 quarter.
Accretion Nutraveda (BSE: ANL) closed at ₹320.00 on 20 Nov 2026. Its market capitalisation is ₹232 crore and it trades at 31.2 times earnings.
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.